Nakamura Tomoki, Matsumine Akihiko, Kawai Akira, Araki Nobuhito, Goto Takahiro, Yonemoto Tsukasa, Sugiura Hideshi, Nishida Yoshihiro, Hiraga Hiroaki, Honoki Kanya, Yasuda Taketoshi, Boku Shogen, Sudo Akihiro, Ueda Takafumi
Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
Division of Orthopedic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Cancer. 2016 May 1;122(9):1408-16. doi: 10.1002/cncr.29961. Epub 2016 Mar 11.
Because the efficacy and safety of pazopanib in Japanese patients with soft tissue sarcoma (STS) had not been evaluated previously in a large-scale cohort, the authors investigated the efficacy and safety of pazopanib in 156 Japanese patients with relapsed STS. This was a retrospective study based on the collection of real-life, postmarketing surveillance data.
Patients received pazopanib with the objective of treating local recurrence (n = 20), metastasis (n = 104), and both (n = 32). The patient median age was 53.8 years. The primary objective of this study was to clarify the efficacy of pazopanib for patients with STS.
The median treatment duration was 28.7 weeks, and the average dose intensity of pazopanib was 609 mg. Adverse events occurred in 127 patients (81.4%). In addition to the main common toxicities, such as hypertension and liver disorder, pneumothorax (n = 11) and thrombocytopenia (n = 16) also were observed. The median progression-free survival for all patients was 15.4 weeks. The median progression-free survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 18.6 weeks, 16.4 weeks, 15.3 weeks, and 8 weeks, respectively. The median survival for all patients was 11.2 months. The median survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 20.1 months, 10.6 months, 9.5 months, and 7.3 months, respectively.
There were apparent differences in the efficacy of pazopanib treatment among histologic types of STS. Pazopanib treatment is a new treatment option; however, adverse events like pneumothorax and thrombocytopenia, which did not occur frequently in the PALETTE study (pazopanib for metastatic soft-tissue sarcoma), should be taken into consideration. Cancer 2016;122:1408-16. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
由于此前尚未在大规模队列中评估帕唑帕尼对日本软组织肉瘤（STS）患者的疗效和安全性，作者调查了帕唑帕尼对156例复发STS日本患者的疗效和安全性。这是一项基于真实生活、上市后监测数据收集的回顾性研究。
患者接受帕唑帕尼治疗，目的是治疗局部复发（n = 20）、转移（n = 104）以及两者皆有（n = 32）的情况。患者中位年龄为53.8岁。本研究的主要目的是明确帕唑帕尼对STS患者的疗效。
中位治疗持续时间为28.7周，帕唑帕尼的平均剂量强度为609毫克。127例患者（81.4%）发生了不良事件。除了高血压和肝脏疾病等主要常见毒性外，还观察到气胸（n = 11）和血小板减少（n = 16）。所有患者的中位无进展生存期为15.4周。平滑肌肉瘤、滑膜肉瘤、未分化多形性肉瘤和脂肪肉瘤患者的中位无进展生存期分别为18.6周、16.4周、15.3周和8周。所有患者的中位生存期为11.2个月。平滑肌肉瘤、滑膜肉瘤、未分化多形性肉瘤和脂肪肉瘤患者的中位生存期分别为20.1个月、10.6个月、9.5个月和7.3个月。
帕唑帕尼治疗在不同组织学类型的STS中的疗效存在明显差异。帕唑帕尼治疗是一种新的治疗选择；然而，应考虑到气胸和血小板减少等不良事件，这些事件在PALETTE研究（帕唑帕尼用于转移性软组织肉瘤）中并不常见。《癌症》2016年；122:1408 - 16。© 2016作者。《癌症》由威利期刊公司代表美国癌症协会出版。
Zotero 插件
